Corvus Pharmaceuticals
(NASDAQ) CRVS
Corvus Pharmaceuticals Financials at a Glance
Market Cap
$1.23B
Revenue (TTM)
$0.00
Net Income (TTM)
$15.28M
EPS (TTM)
$-0.51
P/E Ratio
-29.02
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$14.74
Volume
22,003
Open
$13.84
Price
$14.74
Volume
22,003
Open
$13.84
Previous Close
$14.74
Daily Range
$13.84 - $14.80
52-Week Range
$2.54 - $26.95
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$14.74
Volume
22,003
Open
$13.84
Previous Close
$14.74
Daily Range
$13.84 - $14.80
52-Week Range
$2.54 - $26.95
CRVS News
CRVS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Corvus Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
37
CEO
Richard A. Miller, MD
Website
www.corvuspharma.comHeadquarters
South San Francisco, CA 94010, US
CRVS Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-33%
Return on Capital
-70%
Return on Assets
-21%
Earnings Yield
-3.45%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.23B
Shares Outstanding
83.99M
Volume
22.00K
Short Interest
0.00%
Avg. Volume
3.42M
Financials (TTM)
Gross Profit
$105.00K
Operating Income
$42.97M
EBITDA
$42.97M
Operating Cash Flow
$32.80M
Capital Expenditure
$174.00K
Free Cash Flow
$32.97M
Cash & ST Invst.
$56.75M
Total Debt
$937.00K
Corvus Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$26.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.23B
N/A
Market Cap/Employee
$39.80M
N/A
Employees
31
N/A
Net Income
$12.32M
-1.7%
EBITDA
$12.19M
-50.8%
Quarterly Fundamentals
Net Cash
$55.81M
+9.8%
Accounts Receivable
$374.00K
+73.1%
Inventory
$0.00
N/A
Long Term Debt
$534.00K
-43.0%
Short Term Debt
$403.00K
+117.8%
Return on Assets
-21.49%
N/A
Return on Invested Capital
-69.60%
N/A
Free Cash Flow
$9.22M
-8.9%
Operating Cash Flow
$9.19M
-8.6%